Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer
Abstract Purpose To investigate the survival outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients receiving first-line novel androgen receptor axis-targeted therapies (ARATs) and prognostic factors for patient survival. Methods This retrospective study obtained data from 202...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BMC
2023-06-01
|
| Seri Bilgileri: | BMC Cancer |
| Konular: | |
| Online Erişim: | https://doi.org/10.1186/s12885-023-10885-4 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|